SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is trending intensely following the FDA approval of YARTEMLEA, its first and only therapy for transplant-associated thrombotic microangiopathy (TA-TMA), a critical condition with no prior approved treatments. The community is buzzing with speculation about the stock's significant undervaluation, potential for a short squeeze, and the possibility of a buyout from Novo Nordisk, building on their existing multi-billion dollar licensing deal.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax is trending significantly following the announcement that Sanofi is acquiring the company for $15.50 per share, a move set to enhance Sanofi's adult immunization portfolio with Dynavax's key vaccine assets. The community is buzzing with discussions about the offer's fairness, with many long-term shareholders expressing frustration over the valuation compared to the stock's historical performance, while others celebrate the substantial immediate gains. This development underscores the continued strategic consolidations within the biotech vaccine sector.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is drawing significant attention after its depression drug failed a Phase 2 study and its SCA treatment received an FDA Complete Response Letter, leading to a company restructuring. Despite these setbacks, substantial insider buying and an intense community focus on highly anticipated data from its epilepsy, obesity, and oncology programs are driving conversations about potential future value. Investors are actively discussing whether the current valuation presents a strategic entry point for its diverse pipeline.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos (ATOM) is trending as community discussions compare its interoperability vision and performance against emerging rivals like Keeta, which champions superior throughput and compliance-first architecture for institutional financial flows. Many investors express frustration over ATOM's prolonged price declines, which often overshadow its high staking rewards, amidst ongoing community efforts to redesign its tokenomics for long-term sustainability.

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.

Mimedx Group Inc

MiMedx Group is trending as recent CMS policy changes are poised to dramatically reshape the advanced wound care market by curbing fraud and prioritizing products with strong clinical evidence. The community is actively debating how these regulations will eliminate many higher-priced competitors, creating a significant market share opportunity for MDXG's proven offerings. Investors are keenly focused on how this shift towards evidence-based reimbursement could drive the company's long-term growth despite initial pricing adjustments.

RAWW MILK COIN

RAWW MILK COIN is buzzing as its community highlights a year of sustained development and continuous content drops, from new webtoons and "Truth Series" videos to an album and game updates. The sentiment centers on RAWW building a unique "anti-degen" lifestyle and expanding into a full cultural universe, rather than just being a typical meme coin. This consistent delivery, even through market volatility, underscores its distinct philosophy and community-driven longevity.

Inflection Point Acquisition Corp. IV is a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Andrew Stephen Gundlach and Michel Combes on June 24, 2024 and is headquartered in New York, NY.

Inflection Point Acquisition Corp. IV - Ordinary Shares - Class A

Bleichroeder Acquisition Corp I

Bleichroeder Acquisition Corp I ($BACQ) is generating significant buzz following multiple bullish reports from Citron Research, highlighting its compelling risk/reward ahead of a merger with Merlin Labs. The community is actively discussing Merlin's advanced AI-enabled autonomous flight technology, substantial defense contracts, and partnerships with major aerospace primes, all seen as strong growth catalysts for the defense tech SPAC. Many view the current valuation favorably due to its perceived limited downside and significant upside potential post-merger.

snowball is the first token in the world that uses the pumpfun creator fees to automatically marketmake itself aggressively.

snowball

SNOWBALL CRYPTO is trending due to community excitement surrounding its innovative script designed to combat "sneaky devs" and prevent "rug pulls," positioning it as a potential "game changer" for new launches on the Solana blockchain. Many users are optimistic about its early-stage potential to foster trust within the market, while some community members advise caution regarding potential pump and dump activity.

OpGen, Inc. is a precision medicine company, which engages in the power of molecular diagnostics and informatics to help combat infectious disease. It focuses on the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Clarksburg, MD.

Opgen Inc

OPGN is gaining significant attention following its strategic pivot to an AI-driven fintech platform, CapForce, which is generating widespread speculation about a potential NASDAQ relisting. The community is buzzing with high expectations for substantial price appreciation, driven by recent compliance filings and the notable backing of its majority shareholder, AEI Capital, despite historical volatility and low trading volume.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is trending amid intense focus on its pivotal role in silicon photonics and co-packaged optics, critical for next-generation AI data centers via collaborations like TSMC's COUPE platform. The community is keenly discussing the potential for substantial revenue growth from these innovations, balancing high anticipation with historical skepticism about stock performance and market maker influence. As a key enabler for surging AI infrastructure demand, investors are watching for a significant revaluation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Top Drone Tech Stocks to Bet on Amid Increasing Adoption

AVAV, KTOS and DPRO are some stocks in the drone technology space that are worthy of investment consideration.

Ondas Holdings' Counter-UAS Push: A Powerful Growth Catalyst?

ONDS is ramping up in the booming counter-drone market with record revenues, strategic acquisitions and a layered detect-to-defeat system.

Ondas Stock Skyrockets Over 725% in a Year: Time to Lock in Profits?

ONDS' 725.5% surge fueled by its fast-growing OAS unit now faces valuation pressure and rising execution risks.

<ul class="summary-bullets"><li>The three companies will evaluate initiatives on defense modernization, maritime and border security, disaster response, and critical infrastructure protection.</li><li>Babcock brings deep defense engineering expertise, CiTech adds advanced digital security systems, and Draganfly brings its rapid-response Commander 3XL drones to the table.</li><li>Draganfly recently signed two separate orders for its Commander 3XL UAM.</li></ul>Draganfly Inc. (DPRO) stock climbed 3% higher on Monday, after the company signed a collaborative framework with Babcock International Group and Critical Infrastructure Technologies Corp. to jointly explore defense and security opportunities across the Asia-Pacific region.The collaboration will align expertise in unmanned systems, mission-critical engineering, and digital architectures.<h2 class="st-heading-2">The Deal</h2>Babcock has substantial experience in fleet management, naval support, training, and defence program delivery for governments and allied militaries worldwide. Critical Infrastructure Technologies, through its CiTech subsidiary, adds advanced digital mission systems, integrated sensor platforms, and technologies for national security. At the same time, Draganfly will provide its unmanned aerial systems (UAMs), including the Commander 3XL, which offer rapid response and aerial intelligence.Together, the companies plan to evaluate initiatives supporting priorities such as defense modernization, maritime and border security, disaster response, and critical infrastructure protection.“By aligning our proven aerial systems with the established capabilities of Babcock and CiTech, we see significant opportunity to contribute to long-term defense modernization programs that require interoperable, high-assurance technologies. The demand for resilient, sovereign mission capabilities across the region continues to grow, and Draganfly is well positioned to support that evolution with dependable, mission-ready solutions,” said Cameron Chell, Chief Executive Officer of Draganfly.<h2 class="st-heading-2">Order Momentum</h2>Last month, Draganfly secured an international military order for its Commander 3XL drones. The company was part of the first phase of a formal evaluation program to expand drone use across military missions.Separately, Draganfly also received a second purchase order from a Fortune 50 telecommunications provider in November. Under that agreement, Draganfly will supply Commander 3XL units to support a drone fleet for emergency response and post-disaster communications.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/DPRO">DPRO</a> on Stocktwits changed to ‘neutral’ from ‘bearish’ a day earlier.One Stocktwits user expects the stock to climb to $10 by the end of the year.<stembedurl>https://stocktwits.com/Crete23/message/638473277</stembedurl>Year-to-date, the stock has seen heavy buying interest, gaining around 90%.&nbsp;Read Also: <a href="https://stocktwits.com/news-articles/markets/equity/is-rivian-losing-its-spark-morgan-stanley-downgrades-amid-ev-winter/cLIYrRtREmJ">Is Rivian Losing Its Spark? Morgan Stanley Downgrades Amid EV 'Winter'</a>&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artistic representation of a trending chart.

Draganfly Stock Takes Off On Fresh Defense Technology Alliance Focused On Asia-Pacific Region

Draganfly signed a collaborative framework with Babcock and Critical Infrastructure Technologies to jointly explore defense and security opportunities across the Asia-Pacific region.

Equity

Will ONDS' Lucrative Border-Defense Win Ignite Its Next Growth Engine?

Ondas' major government tender win for a large autonomous border-defense drone program boosts its growth outlook and strengthens future revenue visibility.

Will ONDS' Strengthened Balance Sheet Fuel Its Defense Ambitions?

Ondas bolsters its cash pile to accelerate defense and autonomous systems expansion and aggressive M&A, amid rising demand.

Is Draganfly (DPRO) Stock Outpacing Its Aerospace Peers This Year?

Here is how Draganfly Inc. (DPRO) and MTU Aero Engines AG (MTUAY) have performed compared to their sector so far this year.

Will $35M PDW Investment Boost ONDS' Next-Gen Robotics Capabilities?

Ondas' $35M push into PDW boosts autonomous defense capabilities, expands production and sets up stronger revenue momentum into 2025 and beyond.

Can ONDS' Acquisition Spree Accelerate Its Multi-Domain Strategy?

Ondas accelerates its multi-domain push with rapid acquisitions spanning robotics, optics, subsurface intelligence and counter-UAS tech.

Will ONDS' $23 Million Backlog Support Its 2026 Growth Target?

Ondas enters Q4 2025 with surging backlog, rapid autonomous systems momentum and expanded reach through strategic acquisitions.

Draganfly, Inc. engages in the manufacture and sale of commercial unmanned aerial vehicle systems and software serving the public safety, agriculture, industrial inspections, security, mapping, and surveying markets. Its products include quad-copters, fixed wing aircrafts, ground based robots, hand held controllers, and software used for tracking, live streaming, and data collection. The firm also offers custom engineering, training, simulation consulting, as well as data and flight training services. The company was founded by Zenon Dragan and Christine Dragan in 1998 and is headquartered in Saskatoon, Canada.

Current Price	$8.10
Prev Close	$8.03
Open	$8.07
Dividend Yield	0.00%
50-Day Moving Average	$8.08
Beta	1.07
Avg. Volume	2.12M
PE Ratio	-4.33

52-Week High	$14.40
52-Week Low	$1.63
Market Capitalization	$186.79M
EPS (Annual)	-$3.21
Price to Book	3.69
Revenue Per Employee	$88,689.37
Enterprise Value/EBITDA	N/A

DPRO
Draganfly Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DPRO News

DPRODraganfly Inc